Discussion on the standardization for the clinical trials of drug therapy for cerebral infarctionSHI Jin, HU Wen-juan917-920,936
Construction of complementary systems relative to registration of genericsZHANG Ning, PING Qi-neng921-925
Development and marketing strategies of me too drugSU Wei-ping, HU Hao, SHI Lu-wen, WANG Yi-tao926-929
Key problems in the development of innovative drugs——scientific rationale and principle requirement of clinical studiesWANG Shui-qiang930-932
Selection, characterization and evaluation for the key technologies in the "key new drug creation and development programme"SUN Yu, GAO Bo, XU Shou-jun, WEI Xiao-qing, ZHANG Yong-xiang933-936
Quality assurance and field inspection of genetic toxicity testsGUO Qiao-zhen, WU Chun-qi, MA Hua-zhi, LIAO Ming-yang, DING Ri-gao937-939
Role of oxidative stress on Alzheimer's disease and research advance of new drugsCHU Ben-hong, DONG Wen-xin940-943,948